GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (OTCPK:NICXF) » Definitions » Additional Paid-In Capital

Nicox (NICXF) Additional Paid-In Capital : $583.03 Mil(As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Nicox Additional Paid-In Capital?


Nicox's quarterly additional paid-in capital increased from Jun. 2022 ($566.72 Mil) to Dec. 2022 ($570.13 Mil) and increased from Dec. 2022 ($570.13 Mil) to Jun. 2023 ($583.03 Mil).

Nicox's annual additional paid-in capital declined from Dec. 2020 ($643.06 Mil) to Dec. 2021 ($605.88 Mil) and declined from Dec. 2021 ($605.88 Mil) to Dec. 2022 ($570.13 Mil).

Nicox Additional Paid-In Capital Historical Data

The historical data trend for Nicox's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nicox Additional Paid-In Capital Chart

Nicox Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 580.98 576.05 643.06 605.88 570.13

Nicox Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 636.76 605.88 566.72 570.13 583.03

Nicox Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Nicox Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Nicox's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Nicox (NICXF) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (OTCPK:NICXF) » Definitions » Additional Paid-In Capital
Comparable Companies
XPAR:PHXM XPAR:ALNFL XPAR:ALVIO XPAR:ALDVI XPAR:ALPAT XPAR:ALTHX XPAR:ALGAE XPAR:ALTME XPAR:ALMDP XPAR:ALACT OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
ALCOX:France NXOA:Germany
Address
2405 route des Dolines, Drakkar 2 -Batiment D, Valbonne, Sophia Antipolis, FRA, 06560
Website
https://www.nicox.com
Nicox SA is an international company specializing in ophthalmology developing solutions aimed at maintaining vision and improving eye health. Nicox's program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It is also conducting research on NCX 1728, a NO-donating phosphodiesterase 5 inhibitor, in retinal diseases. NCX 4251, a patented ophthalmic suspension of fluticasone propionate nanocrystals, for topical ocular application for dry eye, is being developed by Ocumension Therapeutics in China. Nicox generates revenue from VYZULTA in glaucoma and ZERVIATE in allergic conjunctivitis.

Nicox (NICXF) Headlines

From GuruFocus

Bausch Health Announces VYZULTA� (latanoprostene bunod ophthalmic solution), 0.024%, is Now Approved in South Korea

By PRNewswire PRNewswire • 02-09-2021